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ABSTRACT
Objective: The aim of the study was to detect the differences in number and distribution of angiotensin II type-1 receptor 
(AT1R) in BPH, high grade PIN, and adenocarcinoma of the prostate. Material & method: A prospective study was 
performed in RSHS, in collaboration with the Department of Anatomical Pathology. Prostate samples were taken by TUR of 
the prostate, and then divided into 5 groups. They were BPH, high grade PIN, adenocarcinoma of the prostate in 3 difference 
grades (well, moderate, and poorly differentiated). Kidney tissue served as control. Immunohistochemical staining was done 
to determine the angiotensin II type-1 (AT1R) receptor distribution as primary antibody mouse monoclonal antibody AT1 
(TONI-1) was used. Results: Angiotensin II type-1 receptor was found in specimen from BPH, high grade PIN and 
adenocarcinoma of the prostate. The number and distribution of the receptors were not different. Conclusion: No significant 
differences in number and distribution of angiotensin II type-1 receptor on BPH, high grade PIN, and adenocarcinoma of the 
prostate were found.
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INTRODUCTION
Prostate carcinogenesis is developing in a lengthy 
process and taking place through several steps due to 
genetic and epigenetic changes that result in balance 
alteration between cell proliferation, apoptosis, and 
differentiation. Normal prostate epithelium requires 
10-30 years to develop into clinically detectable 
prostate cancer, and 10-20 years later into metastasis. 
Therefore, theoretically there is a chance to prevent 
1
prostatic malignancy with chemoprevention.  
Angiotensin, particularly angiotensin II type-1 has 
cell proliferative effect (Diem T et al. 2001), in 
2
addition to the vasocontrictive effect.  The role of 
angiotensin in the development of prostatic cells has 
not be recognized. To find the role of angiotensin in 
prostate cells, the presence and distribution 
angiotensin II type-1 receptor (AT1R) in prostate 
tissue should be identified.
OBJECTIVE
To compare the distribution of angiotensin II type-
1 receptor (AT1R) in BPH, high grade PIN, and 
prostate adenocarcinoma.
MATERIAL & METHOD
We studied the expression and compare the 
distribution of angiotensin II type-1 receptor (AT1R) 
in different types of pathology of the prostate, such as 
BPH, high grade PIN, and prostate adenocarcinoma 
immunohistochemically. The objects of study were 10 
samples of BPH, 10 preparations of high grade PIN 
and 10 preparations of prostate adenocarcinoma. As 
primary antibody mouse monoclonal antibody AT1 
(TONI-1): sc-57036, Santa Cruz Biotechnology, Inc., 
CA. was used.
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Figure 1. The expression of angiotensin II type-1 (AT1R) in 
BPH.
Figure 2. The expression of angiotensin II type-1 (AT1R) in 
high grade PIN.
Figure 3. The expression of angiotensin II type-1 (AT1R) in 
prostate adenocarcinoma. 
RESULTS
From the immunohistochemical examination of 
all tissue samples, we found expression of the 
angiotensin II type-1 (AT1R) receptor in all prostate 
tissues (BPH, high grade PIN, and prostate 
adenocarcinoma). The receptor expression was in 
brown color. The distribution of angiotensin II type-1 
receptor (AT1R) was found in the stroma cells of 
prostatic tissue in all preparations with equal intensity. 
There was no expression in epithelium cells.
Table 1. The expression of angiotensin II type-1 (AT1R). 
Types of tissue
Expression of angiotensin II 
type-1 Receptor ( AT1R )
BPH
High grade PIN
AdenoCa
Epithelium
-
-
-
Stroma
presence
+
+
+
Stroma
intensity
++
++
++
DISCUSSION
In vitro studies revealed that angiotensin II 
receptor in human prostate tissue is predominated by 
the AT1 subtype and mostly present in the periurethral 
area. Immunohistochemistry showed the AT1 receptor 
was located in the cells of muscular stroma. In several 
tissues, angiotensin II was found to increase the tonus 
3
of smooth muscles,  and to stimulate cell proliferation 
2,4
and growth.  It is very likely that angiotensin II 
enhances also cellular growth and increases 
symphatic tonus in the prostate. Both are the factors 
5,6
that play role in the pathophysiology of BPH.  It has 
been shown that angiotensin II facilitates symphatetic 
7
transmission,  by enhancing the release of the 
noradrenalin neurotransmitter from a symphatetic 
nerver terminal.
Angiotensin II has a mitogenic effect on various 
cells, such as blood vessel smooth muscle cells, 
hepatic stellate cells, fibroblasts, hematopoietic 
progenitor cells, and mesothelial cells. There are two 
types of angiotensin II receptor that play here a role, 
i.e., angiotensin 1 (AT1) receptor and angiotensin-2 
(AT2) receptor. The mitogenic effect and blood 
pressure regulation is regulated by AT1 receptor. Latin 
et al. (2000) found that malignancy in the prostate is 
mediated by angiogenesis, which in this case is caused 
1
by the vascular endothelial growth factor (VEGF).  
The increase of VEGF correlates with clinical 
aggressiveness. Angiotensin II also plays a role in 
cytokine secretion, and the cytokine is involved in 
angiogenesis. Blockade to angiotensin II specific 
receptor may inhibit VEGF production, leading to the 
8-12
inhibition of the angiogenetic process.
56
JURI, Vol. 17.  No. 2.  July  2010: 55-57
In this study, we performed immunohistochemical 
examination to observe AT1 receptor in prostate tissue 
and its distribution, with the finding that there was 
angiotensin II type-1 receptor in the preparations of 
BPH, high grade PIN, and prostate adenocarcinoma. 
The number and distribution of angiotensin II type-1 in 
the preparations of BPH, high grade PIN, and prostate 
adenocarcinoma were not different. This was likely 
because the sample was taken from the periurethral 
zone with a TURP, while prostate adenocarcinoma 
occurs most frequently in peripheral zone. Studies 
using an intact prostate sample such as from radical 
prostatectomy operation are needed to observe AT1 
receptor distribution in the required prostate zone.
CONCLUSION
Angiotensin II type-1 receptor is present in the 
preparations of BPH, high grade PIN, and prostate 
adenocarcinoma. The number and distribution of 
angiotensin II type-1 receptor in those preparations are 
the same in all tissues.
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